Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for a Nonopioid Analgesic Candidate in Acute Postoperative Pain
The most common error in an IND annual report is not in its content but in its clock: the deadline runs from the anniversary of the date the IND went into effect, not from a marketing approval or a recent protocol amendment. This article prepares the regulatory operations components of the first annual report for a hypothetical open IND for an oral nonopioid analgesic candidate studied in acute postoperative pain after unilateral total knee arthroplasty. It accounts for a completed Phase 1 study (24 entered) and an ongoing Phase 2 study (36 of 120 entered), tabulates demographics, maps every required element to Module 1.13 of the eCTD, completes Form FDA 1571 as an academic specimen, drafts a cover letter, and sets out a timeline to an April 30, 2027 deadline. It explains why zero IND safety reports does not mean zero serious events and how the DSUR alternative would change the package.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle
Authors
- Peivand Pirouzi
- Perpetua Ulofu
- Uchechukwu Veronica Ikechukwu
- Yemurayi Hungwe
- Precious Chinenye Sunday
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24419717
- Primary Topic
- Healthcare Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00